Pyxis Oncology is trading 8.62% down at $3.50 after a sharp reversal from recent gains.
- Recent gains included a 19.81% rise on August 6 and a 14.72% rise on August 3.
- No new company announcement dated August 11 was identified; its investor-relations page lists June 30 as the latest release.
- Broader markets are only modestly lower, with no clear company-specific or market-wide catalyst explaining the decline.